The effect of bariatric surgery on intestinal absorption and transit time

Obesity Surgery

Volumn 24, Issue 5, 2014, Pages 796-805

  Carswell, Kirstin A ^a   Vincent, Royce P ^a   Belgaumkar, Ajay P ^a   Sherwood, Roy A ^a   Amiel, Stephanie A ^b   Patel, Ameet G ^a   Le Roux, Carel W ^a,c  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Bariatric surgery; Bariatrics; Biliopancreatic diversion; Gastric bypass; Intestinal absorption

Indexed keywords

CALGRANULIN; CITRULLINE; ELASTASE; LACTULOSE; RHAMNOSE; SALAZOSULFAPYRIDINE; SULFAPYRIDINE; XYLOSE;

ADAPTATION; ADULT; ARTICLE; BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; BODY MASS; CELLULAR PARAMETERS; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE SEVERITY; FECES ANALYSIS; FEMALE; FUNCTIONAL ENTEROCYTE MASS; GASTRIC BANDING; HUMAN; INTESTINE ABSORPTION; INTESTINE CELL; INTESTINE MUCOSA PERMEABILITY; INTESTINE TRANSIT TIME; MALABSORPTION; MALE; PANCREAS FUNCTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; ROUX Y ANASTOMOSIS; SMALL INTESTINE; URINARY EXCRETION; CROSS-SECTIONAL STUDY; GASTROINTESTINAL TRACT; GASTROINTESTINAL TRANSIT; GASTROPLASTY; INTESTINE MUCOSA; METABOLISM; MIDDLE AGED; OBESITY, MORBID; STOMACH BYPASS; SURGERY; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; BARIATRIC SURGERY; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; ENGLAND; FEMALE; GASTRIC BYPASS; GASTROINTESTINAL TRACT; GASTROINTESTINAL TRANSIT; GASTROPLASTY; HUMANS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; LACTULOSE; MALE; MIDDLE AGED; OBESITY, MORBID; RHAMNOSE; TREATMENT OUTCOME; XYLOSE;

EID: 84898043312     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-013-1166-x     Document Type: Article

References (94)

1. O'Brien PE. Bariatric surgery: mechanisms, indications and outcomes. J Gastroenterol Hepatol. 2010;25:1358-65.
2. Brolin RE, Kenler HA, Gorman JH, et al. Long-limb gastric bypass in the superobese: a prospective randomised study. Ann Surg. 1992;215:387-95.
3. Scopinaro N, Gianetta E, Civalleri D, et al. Biliopancreatic bypass for obesity: initial experience in man. Br J Surg. 1979;66:618-20.
4. Scopinaro N, Gianetta E, Adami GF, et al. Biliopancreatic diversion for obesity at eighteen years. Surgery. 1996;119:261-8.
5. Hess DS, Hess DW. Biliopancreatic diversion with a duodenal switch. Obes Surg. 1998;8:267-82.
6. Marceau P, Hould FS, Simard S, et al. Biliopancreatic diversion with duodenal switch. World J Surg. 1998;22:947-54.
7. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724-37.
8. Sovik TT, Aashelm ET, Taha O, et al. Weight loss, cardiovascular risk factors, and quality of life after gastric bypass and duodenal switch. Ann Intern Med. 2011;155:281-91.
9. Kennedy M, Chinwah P, Wade DN. A pharmacological method of measuring mouth caecal transit time in man. Br J Clin Pharmacol. 1979;8:372-3.
10. Kellow JE, Borody TJ, Phillip SF, et al. Sulfapyridine appearance in plasma after salicylazosulfapyridine. Gastroenterology. 1986;91:396-400.
11. Saniforth DH. Comparison of oro-caecal transit times assessed by the lactulose/breath hydrogen and the sulphasalazine/sulphapyridine methods. Gut. 1989;30:978-82.
12. Chungi VS, Rekhi GS, Shargel L. A simple and rapid liquid chromatographic method for the determination of major metabolites of sulphasalazine in biological fluids. J Pharmaceut Sci. 1989;78:235-8.
13. Curis E, Crenn P, Cynober L. Citrulline and the gut. Curr Opin Clin Nutr Metab Care. 2007;10:620-6.
14. Weber FL, Reiser BJ. Relationship of plasma amino acids to nitrogen balance and portal-systemic encephalopathy in alcoholic liver disease. Dig Dis Sci. 1982;27:103-9.
15. Papadia C, Sherwood RA, Kalantzis C, et al. Plasma citrulline concentration: a reliable marker of small bowel absorptive capacity independent of intestinal inflammation. Am J Gastroenterol. 2007;102:1474-82.
16. Sherwood RA. Amino acid measurement by high performance liquid chromatography using electrochemical detection. J Neurosci Methods. 1990;34:17-22.
17. Stein J, Jung M, Sziegoleit A, et al. Immunoreactive elastase 1: clinical evaluation of a new noninvasive test of pancreatic function. Clin Chem. 1996;42:222-6.
18. Dominguez-Munoz JE, Hieronymus C, Sauerbruch T, et al. Fecal elastase test: evaluation of a new noninvasive pancreatic function test. Am J Gastroenterol. 1995;90:1834-7.
19. Symersky T, van der Zon A, Biemond I, et al. Faecal elastase-1: helpful in analysing streatorrhoea? Neth J Med. 2004;62:286-9.
20. Kampanis P, Ford L, Berg J. Development and validation of an improved test for the measurement of human faecal elastase-1. Ann Clin Biochem. 2009;46:33-7.
21. Thomas PD, Forbes A, Green J et al. Guidelines for the investigation of chronic diarrhoea. Gut 2003;52(suppl V):v1-5.
22. Duncan A, Hill PG. A review of the quality of gastrointestinal investigations performed in UK laboratories. Ann Clin Biochem. 2007;44:145-58.
23. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:524-34.
24. Lundberg JO, Hellstrom PM, Fagerhol MK, et al. Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2:96-102.
25. Fagerhol MK. Calprotectin, a faecal marker or organic gastrointestinal abnormality. Lancet. 2000;356:1783-4.
26. Van de Kamer JH, Bokkel Huinink HT, Weyers HA. Rapid method for the determination of fat in feces. J Biol Chem. 1949;177:347-55.
27. Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview. Gastroenterol. 1995;108:1566-81.
28. Derikx JPM, Luyer MDP, Heineman E, et al. Non-invasive markers of gut wall integrity in health and disease. World J Gastroenterol. 2010;16:5272-9.
29. Sharpstone D, Neild P, Crane R, et al. Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhoea. Gut. 1999;45:70-6.
30. Burton PR, Yap K, Brown WA, et al. Effects of adjustable gastric bands on gastric emptying, supra- and infraband transit and satiety: a randomized double-blind crossover trial using a new technique of band visualization. Obes Surg. 2010;20:1690-7.
31. Dixon AFR, Dixon JB, O'Brien PE. Laparoscopic adjustable gastric banding induces prolonged satiety: a randomized blind crossover study. J Clin Endocrinol Metab. 2005;90:813-9.
32. Naslund I. The size of the gastric outlet and the outcome of surgery for obesity. Acta Chir Scand. 1986;152:205-10.
33. Nishie A, Brown B, Barloon T, et al. Comparison of size of proximal gastric pouch and short-term weight loss following routine upper gastrointestinal contrast study after laparoscopic Roux-en-Y gastric bypass. Obes Surg. 2007;17:1183-8.
34. O'Connor EA, Carlin AM. Lack or correlation between variation in small-volume gastric pouch size and weight loss after laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2008;4:399-403.
35. Madan AK, Tichansky DS, Phillips JC. Does pouch size matter? Obes Surg. 2007;17:317-20.
36. Halverson JD, Koehler RE. Gastric bypass: analysis of weight loss and factors determining success. Surgery. 1981;90:446-55.
37. Roberts K, Duffy A, Kaufman J, et al. Size matters: gastric pouch size correlates with weight loss after laparoscopic Roux-en-Y gastric bypass. Surg Endosc. 2007;21:1397-402.
38. Björklund P, Laurenius A, Een E, et al. Is the Roux limb a determinant for meal size after gastric bypass surgery? Obes Surg. 2010;20:1408-14.
39. Scopinaro N, Gianetta E, Civalleri D, et al. Two years of clinical experience with bilio-pancreatic bypass for obesity. Am J Clin Nutr. 1980;33:506-14.
40. Morinigo R, Moize V, Musri M, et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2006;91:1735-40.
41. Hould FS, Lagace M, Marceau P, et al. Hastened gastric emptying after partial gastrectomy and duodenal switch. Obes Surg. 1996;6:121-2.
42. Hedburg J, Hedenstrom H, Karlsson FA, et al. Gastric emptying and postprandial PYY response after biliopancreatic diversion with duodenal switch. Obes Surg. 2011;21:609-15.
43. Naslund I, Beckman K-W. Gastric emptying rate after gastric bypass and gastroplasty. Scand J Gastroenterol. 1987;22:193-201.
44. Horowitz M, Cook DJ, Collins PJ, et al. Measurement of gastric emptying after gastric bypass surgery using radionuclides. Br J Surg. 1982;69:655-7.
45. Pellegrini CA, Deveney CW, Patti MG, et al. Intestinal transit of food after total gastrectomy and Roux-en-Y esophagojejunostomy. Am J Surg. 1986;151:177-85.
46. Gonlachanvit S, Coleski R, Owyang C, et al. Inhibitory actions of a high fibre diet on intestinal gas transit in healthy volunteers. Gut. 2004;53:1577-82.
47. Flint A, Raben A, Ersboll AK, et al. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes. 2001;25:781-92.
48. Read NW, Cammack J, Edwards C, et al. Is the transit time of a meal through the small intestine related to the rate at which it leaves the stomach? Gut. 1982;23:824-8.
49. Skroubis G, Sakellaropoulos G, Pouggouras K, et al. Comparison of nutritional deficiencies after Roux-en-Y gastric bypass and after biliopancreatic diversion with a Roux-en-Y gastric bypass. Obes Surg. 2002;12:551-8.
50. DiBaise JK, Young RJ, Vanderhoof JA. Intestinal rehabilitation and the short bowel syndrome: part 1. Am J Gastroenterol. 2004;99:1386-95.
51. Le Roux CW, Borg C, Wallis K, et al. Gut hypertrophy after gastric bypass is associated with increased glucagon-like peptide 2 and intestinal crypt cell proliferation. Ann Surg. 2010;252:50-6.
52. Stock-Damge C, Aprahamian M, Raul F, et al. Small-intestinal and colonic changes after biliopancreatic bypass for morbid obesity. Scand J Gastroenterol. 1986;21:1115-23.
53. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol. 2003;17:161-71.
54. Estall JL, Drucker DJ. Dual regulation of cell proliferation and survival via activation of glucagon-like peptide-2 receptor signalling. J Nutr. 2003;133:3708-11.
55. Jeppesen PB. Clinical significance of GLP-2 in short-bowel syndrome. J Nutr. 2003;133:3721-4.
56. Mason EE, Munns JR, Kealey GP, et al. Effect of gastric bypass on gastric secretion. Am J Surg. 1976;131:162-8.
57. Ponsky TA, Brody F, Pucci E. Alterations in gastrointestinal physiology after Roux-en-Y gastric bypass. Am Coll Surg. 2005;201:125-31.
58. Satake K, Nishiwaki H, Uneyama K. Comparative studies of plasma secretin response after reconstructive surgery of the stomach and pancreas. Ann Surg. 1985;201:447-51.
59. Emas S, Billings A, Grossman MI. Effects of gastrin and pentagastrin on gastric and pancreatic secretion in dogs. Scand J Gastroenterol. 1968;3:234-40.
60. Mason EE, Ito C. Gastric bypass. Ann Surg. 1969;170:329-36.
61. Borg CM, le Roux CW, Ghatei MA, et al. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg. 2006;93:210-5.
62. Borg CM, le Roux CW, Ghatei MA, et al. Biliopancreatic diversion in rats is associated with intestinal hypertrophy and with increased GLP-1, GLP-2 and PYY levels. Obes Surg. 2007;17:1193-8.
63. le Roux CW, Aylwin SJB, Batterham RL, et al. Gut hormone profiles following bariatric surgery favour an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243:108-14.
64. Wettergren A, Schjoldager B, Mortensen PE, et al. Truncated GLP-1 (Proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci. 1993;38:665-73.
65. Wettergren A, Petersen H, Orskov C, et al. Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand J Gastroenterol. 1994;29:501-5.
66. Lluis F, Gomez G, Fujimura M, et al. Peptide YY inhibits nutrient-, hormonal-, and vagally stimulated pancreatic exocrine secretion. Pancreas. 1987;2:454-62.
67. Lluis F, Gomez M, Fujimura M, et al. Peptide YY inhibits pancreatic secretion by inhibiting cholecystokinin release in the dog. Gastroenterol. 1988;94:137-44.
68. Allen JM, Fitzpatrick ML, Yeats JC, et al. Effects of peptide YY and neuropeptide Y on gastric emptying in man. Digestion. 1984;30:255-62.
69. Pappas TN, Debas HT, Goto Y, et al. Peptide YY inhibits meal-stimulated pancreatic and gastric secretion. Am J Physiol Gastrointest Liver Physiol. 1985;248:G118-23.
70. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860-7.
71. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115:1111-9.
72. Nijhuis J, Rensen SS, Slaats Y, et al. Neutrophil activation in morbid obesity, chronic activation of acute inflammation. Obesity. 2009;17:2014-8.
73. Park HK, Sinar DR, Sloss RR, et al. Histologic and endoscopic studies before and after gastric bypass surgery. Arch Pathol Lab Med. 1986;110:1164-7.
74. Sinar DR, Flickinger EG, Park HK, et al. Retrograde endoscopy of the bypassed stomach segment after gastric bypass surgery: unexpected lesions. South Med J. 1985;78:255-8.
75. Flickinger EG, Sinar DR, Pories WJ, et al. The bypassed stomach. Am J Surg. 1985;149:151-6.
76. Martinez-Augustin O, Sanchez de Medina F. Intestinal bile acid physiology and pathophysiology. World J Gastroenterol. 2008;14:5630-40.
77. Pezzilli R, Barassi A, Morselli-Labate AM, et al. Fecal calprotectin and elastase 1 determinations in patients with pancreatic diseases: a possible link between pancreatic insufficiency and intestinal inflammation. J Gastroenterol. 2007;42:754-60.
78. Ito C, Mason EE. Gastric bypass and pancreatic secretion. Surgery. 1971;69:526-32.
79. Choban PS, Flancbaum L. The effect of roux limb lengths on outcome after Roux-en-Y gastric bypass: a prospective, randomized clinical trial. Obes Surg. 2004;12:540-5.
80. Feng JJ, Gagner M, Pomp A, et al. Effect of standard vs extended Roux limb length on weight loss outcomes after laparoscopic Roux-en-Y gastric bypass. Surg Endosc. 2003;17:1055-60.
81. Inabnet WB, Quinn T, Gagner M, et al. Laparoscopic Roux-en-Y gastric bypass in patients with BMI <50: a prospective randomized trial comparing short and long limb lengths. Obes Surg. 2005;15:51-7.
82. Orci L, Chilcott M, Huber O. Short versus long Roux-limb length in Roux-en-Y gastric bypass surgery for the treatment of morbid and super obesity: a systematic review of the literature. Obes Surg. 2011;21:797-804.
83. Odstrcil EA, Martinez JG, Santa Ana CA, et al. The contribution of malabsorption to the reduction in net energy absorption after long-limb Roux-en-Y gastric bypass. Am J Clin Nutr. 2010;92:704-13.
84. Kumar R, Lieske JC, Collazo-Clavell ML, et al. Fat malabsorption and increased intestinal oxalate absorption are common after Roux-en-Y gastric bypass surgery. Surgery. 2011;149:654-61.
85. Mingrone G, DeGaetano A, Greco AV, et al. Reversibility of insulin resistance in obese diabetic patients: role of plasma lipids. Diabetologia. 1997;40:599-605.
86. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57:1470-81.
87. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endo Metab. 2004;89:2608-15.
88. le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg. 2007;246:780-5.
89. Tolessa T, Gutniak M, Holst JJ, et al. Inhibitory effect of glucagon-like peptide-1 on small bowel motility. J Clin Invest. 1998;102:764-74.
90. Tolessa T, Gutniak M, Holst JJ, et al. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat. Dig Dis Sci. 1998;43:2284-90.
91. O'Brien PE, McPhail T, Chaston TB, et al. Systematic review of medium-term weight loss after bariatric surgery. Obes Surg. 2006;16:1032-40.
92. Olbers T, Bjorkman S, Lindroos A, et al. Body composition, dietary intake and energy expenditure after laparoscopic Roux-en-Y gastric bypass and laparoscopic vertical banded gastroplasty: a randomized clinical trial. Ann Surg. 2006;244:715-22.
93. Schoeller DA. Limitations in the assessment of dietary energy intake by self-report. Metabolism. 1995;44:18-22.
94. Lichtman SW, Pisarska K, Berman ER, et al. Discrepancy between self-reported and actual caloric intake and exercise in obese subjects. N Engl J Med. 1992;327:1893-8.